TCGA-97-8172, TCGA-97-8172SENT_1,"SURGICAL PATHOLOGY REPORT","{SURGICAL,PATHOLOGY,REPORT}","{surgical,pathology,report}","{JJ,NN,NN}","{3,3,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_2,"COLLECTION DATE : ?","{COLLECTION,DATE,:,?}","{COLLECTION,DATE,:,?}","{NNP,NNP,:,CD}","{2,0,0,2}","{}"
TCGA-97-8172, TCGA-97-8172SENT_3,"SPECIIVIENS : 1 .","{SPECIIVIENS,:,1,.}","{SPECIIVIENS,:,1,.}","{NNP,:,CD,.}","{0,0,1,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_4,"LUNG , RIGHT UPPER LOBE 2 .","{LUNG,,,RIGHT,UPPER,LOBE,2,.}","{lung,,,RIGHT,UPPER,lobe,2,.}","{NN,,,NNP,NNP,NN,CD,.}","{0,0,4,1,4,5,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_5,"STATION 10 LYMPH NODE 3 .","{STATION,10,LYMPH,NODE,3,.}","{station,10,lymph,node,3,.}","{NN,CD,NN,NN,CD,.}","{4,4,4,0,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_6,"STATION 11 LYMPH NODE 4 .","{STATION,11,LYMPH,NODE,4,.}","{station,11,lymph,node,4,.}","{NN,CD,NN,NN,CD,.}","{4,4,4,0,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_7,"STATION 2 AND 4 LYMPH NODE 5 .","{STATION,2,AND,4,LYMPH,NODE,5,.}","{station,2,and,4,lymph,node,5,.}","{NN,CD,CC,CD,NN,NN,CD,.}","{0,1,0,6,6,1,1,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_8,"STATION 7 LYMPH NODE SEE ADDENDUM","{STATION,7,LYMPH,NODE,SEE,ADDENDUM}","{station,7,lymph,node,see,addendum}","{NN,CD,NN,NN,VBP,NN}","{4,4,4,0,4,5}","{}"
TCGA-97-8172, TCGA-97-8172SENT_9,"Reason For Addendum # 1 : Molecular Studies Reason For Addendum # 2 : Molecular Studies Reason For Addendum # 3 : Molecular Studies DIAGNOSIS :","{Reason,For,Addendum,#,1,:,Molecular,Studies,Reason,For,Addendum,#,2,:,Molecular,Studies,Reason,For,Addendum,#,3,:,Molecular,Studies,DIAGNOSIS,:}","{reason,for,Addendum,#,1,:,molecular,study,reason,for,Addendum,#,2,:,molecular,study,reason,for,Addendum,#,3,:,molecular,study,diagnosis,:}","{NN,IN,NNP,#,CD,:,JJ,NNS,NN,IN,NNP,#,CD,:,JJ,NNS,NN,IN,NNP,#,CD,:,JJ,NNS,NNS,:}","{0,0,1,5,1,0,9,9,1,0,9,13,11,0,17,17,1,0,17,21,19,0,24,1,24,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_10,"1 .","{1,.}","{1,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_11,"LUNG , RIGHT UPPER LOBE : LOBECTOMY - ADENOCARCINOMA , ACINAR PREDOMINANT ( 3.5 CM ) , SEE NOTE .","{LUNG,,,RIGHT,UPPER,LOBE,:,LOBECTOMY,-,ADENOCARCINOMA,,,ACINAR,PREDOMINANT,(,3.5,CM,),,,SEE,NOTE,.}","{lung,,,RIGHT,UPPER,LOBE,:,lobectomy,-,adenocarcinoma,,,ACINAR,predominant,(,3.5,cm,),,,see,note,.}","{NN,,,NNP,NNP,NNP,:,NN,:,NN,,,NNP,JJ,NN,CD,NN,NN,,,VBP,VB,.}","{0,0,5,5,1,0,1,0,18,0,13,13,9,16,16,13,0,1,18,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_12,"- THE BRONCHIAL AND VASCULAR MARGINS ARE FREE OF TUMOR .","{-,THE,BRONCHIAL,AND,VASCULAR,MARGINS,ARE,FREE,OF,TUMOR,.}","{-,the,bronchial,and,vascular,margin,be,free,of,tumor,.}","{:,DT,NN,CC,NN,NNS,VBP,NNS,IN,NN,.}","{0,3,8,0,6,3,8,0,0,8,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_13,"- SEVEN LYMPH NODES , NEGATIVE FOR CARCINOMA ( 0/7 ) .","{-,SEVEN,LYMPH,NODES,,,NEGATIVE,FOR,CARCINOMA,(,0/7,),.}","{-,seven,LYMPH,NODES,,,NEGATIVE,for,CARCINOMA,(,0/7,),.}","{:,CD,NNP,NNP,,,NNP,IN,NNP,CD,CD,NN,.}","{0,4,4,0,0,4,0,4,8,11,8,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_14,"Note : The tumor consists of acinar ( 90 % ) and lepidic ( 10 % ) components and has prominent extracellular mucin .","{Note,:,The,tumor,consists,of,acinar,(,90,%,),and,lepidic,(,10,%,),components,and,has,prominent,extracellular,mucin,.}","{note,:,the,tumor,consist,of,acinar,(,90,%,),and,lepidic,(,10,%,),component,and,have,prominent,extracellular,mucin,.}","{VB,:,DT,NN,VBZ,IN,JJ,NN,CD,NN,CD,CC,JJ,NN,CD,NN,CD,NNS,CC,VBZ,JJ,JJ,NN,.}","{0,0,4,20,1,0,8,5,10,8,8,0,14,5,16,14,18,14,0,5,23,23,20,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_15,"An elastic stain is inde?nite for visceral pleural invasion and a mucin stain is non-contributory .","{An,elastic,stain,is,inde?nite,for,visceral,pleural,invasion,and,a,mucin,stain,is,non-contributory,.}","{a,elastic,stain,be,inde?nite,for,visceral,pleural,invasion,and,a,mucin,stain,be,non-contributory,.}","{DT,JJ,VBP,VBZ,NN,IN,JJ,JJ,NN,CC,DT,NN,VB,VBZ,JJ,.}","{2,3,0,5,3,0,9,9,5,0,12,15,12,15,3,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_16,"Results of mutational studies will be reported in addenda .","{Results,of,mutational,studies,will,be,reported,in,addenda,.}","{result,of,mutational,study,will,be,report,in,addendum,.}","{NNS,IN,JJ,NNS,MD,VB,VBN,IN,NN,.}","{7,0,4,1,7,7,0,0,7,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_17,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_18,"LYMPH NODE , LEVEL 10 : BIOPSY - FIVE LYMPH NODES , NEGATIVE FOR CARCINOMA ( 0/5 ) .","{LYMPH,NODE,,,LEVEL,10,:,BIOPSY,-,FIVE,LYMPH,NODES,,,NEGATIVE,FOR,CARCINOMA,(,0/5,),.}","{lymph,node,,,level,10,:,biopsy,-,five,LYMPH,NODES,,,NEGATIVE,for,CARCINOMA,(,0/5,),.}","{NN,NN,,,NN,CD,:,NN,:,CD,NNP,NNP,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,2,4,0,2,0,11,11,7,0,2,0,13,15,18,13,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_19,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_20,"LYMPH NODE , LEVEL 11 : BIOPSY - FIVE LYMPH NODES , NEGATIVE FOR CARCINOMA ( 0/5 ) .","{LYMPH,NODE,,,LEVEL,11,:,BIOPSY,-,FIVE,LYMPH,NODES,,,NEGATIVE,FOR,CARCINOMA,(,0/5,),.}","{lymph,node,,,level,11,:,biopsy,-,five,LYMPH,NODES,,,NEGATIVE,for,CARCINOMA,(,0/5,),.}","{NN,NN,,,NN,CD,:,NN,:,CD,NNP,NNP,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,2,4,0,2,0,11,11,7,0,2,0,13,15,18,13,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_21,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_22,"LYMPH NODE , LEVELS 2 AND 4 : BIOPSIES - NINE LYMPH NODES , NEGATIVE FOR CARCINOMA ( 0/9 ) .","{LYMPH,NODE,,,LEVELS,2,AND,4,:,BIOPSIES,-,NINE,LYMPH,NODES,,,NEGATIVE,FOR,CARCINOMA,(,0/9,),.}","{lymph,node,,,level,2,and,4,:,biopsy,-,nine,LYMPH,NODES,,,NEGATIVE,for,CARCINOMA,(,0/9,),.}","{NN,NN,,,NN,CD,CC,CD,:,NNS,:,CD,NNP,NNP,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,2,4,0,4,0,2,0,13,13,9,0,13,0,15,17,20,15,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_23,"5 .","{5,.}","{5,.}","{CD,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_24,"LYMPH NODE , LEVEL 7 : BIOPSY - SIX LYMPH NODES , NEGATIVE FOR CARCINOMA ( 0/6 ) .","{LYMPH,NODE,,,LEVEL,7,:,BIOPSY,-,SIX,LYMPH,NODES,,,NEGATIVE,FOR,CARCINOMA,(,0/6,),.}","{lymph,node,,,level,7,:,biopsy,-,six,lymph,node,,,NEGATIVE,for,CARCINOMA,(,0/6,),.}","{NN,NN,,,NN,CD,:,NN,:,CD,NN,NNS,,,NNP,IN,NNP,CD,CD,NN,.}","{2,0,0,2,4,0,2,0,11,11,7,0,2,0,13,15,18,13,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_25,"Specimens : 1 : LUNG , RIGHT UPPER LOBE 2 : STATION 10 LYMPH NODE 3 : STATION 11 LYMPH NODE 4 : STATION 2 AND 4 LYMPH NODE 5 : STATION 7 LYMPH NODE","{Specimens,:,1,:,LUNG,,,RIGHT,UPPER,LOBE,2,:,STATION,10,LYMPH,NODE,3,:,STATION,11,LYMPH,NODE,4,:,STATION,2,AND,4,LYMPH,NODE,5,:,STATION,7,LYMPH,NODE}","{specimen,:,1,:,lung,,,RIGHT,UPPER,lobe,2,:,station,10,LYMPH,NODE,3,:,station,11,lymph,node,4,:,station,2,and,4,lymph,node,5,:,station,7,lymph,node}","{NNS,:,CD,:,NN,,,NNP,NNP,NN,CD,:,NN,CD,NNP,NNP,CD,:,NN,CD,NN,NN,CD,:,NN,CD,CC,CD,NN,NN,CD,:,NN,CD,NN,NN}","{0,0,1,0,3,0,9,9,5,9,0,15,15,15,5,15,0,21,21,21,5,21,0,5,24,0,29,29,5,29,0,5,35,35,32}","{}"
TCGA-97-8172, TCGA-97-8172SENT_26,"LUNG : Resection SPECIMEN Specimen : Lung Procedure : Lobectomy Specimen Integrity : Intact Specimen Laterality : Right Tumor Site : Upper lobe Tumor Focality : Unifocal TUMOR Histologic Type : Adenocarcinoma Histologic Grade : G2 : Moderately differentiated EXTENT Tumor Size : Greatest dimension ( cm ) 3.5 cm Visceral Pleura Invasion : Not identified MARGINS Bronchial Margin Bronchial Margin Involvement by Invasive Carcinoma : Uninvolved by invasive carcinoma Vascular Margin : Uninvolved by invasive carcinoma ACCESSORY FINDINGS Lymph-Vascular Invasion : Not identified STAGE ( pTNM ) Primary Tumor ( pT ) : pT2a : Tumor greater than 3 cm , but 5 cm or less in greatest dimension surrounded by lung or visceral pleura without bronchoscopic evidence of invasion more proximal than the lobar bronchus ( i.e. , not in the main bronchus ) ; or Tumor 5 cm or less in greatest dimension with any of the following features of extent : involves main bronchus , 2 cm or more distal to the carina ; invades the visceral pleura ; associated with atelectasis or obstructive pneumonitis that extends to the hilar region but does not inolve the entire lung Regional Lymph Nodes ( pN ) pNo : No regional lymph node metastasis Number Examined 32 Number Involved o Distant Metastases ( pM ) : Not applicable","{LUNG,:,Resection,SPECIMEN,Specimen,:,Lung,Procedure,:,Lobectomy,Specimen,Integrity,:,Intact,Specimen,Laterality,:,Right,Tumor,Site,:,Upper,lobe,Tumor,Focality,:,Unifocal,TUMOR,Histologic,Type,:,Adenocarcinoma,Histologic,Grade,:,G2,:,Moderately,differentiated,EXTENT,Tumor,Size,:,Greatest,dimension,(,cm,),3.5,cm,Visceral,Pleura,Invasion,:,Not,identified,MARGINS,Bronchial,Margin,Bronchial,Margin,Involvement,by,Invasive,Carcinoma,:,Uninvolved,by,invasive,carcinoma,Vascular,Margin,:,Uninvolved,by,invasive,carcinoma,ACCESSORY,FINDINGS,Lymph-Vascular,Invasion,:,Not,identified,STAGE,(,pTNM,),Primary,Tumor,(,pT,),:,pT2a,:,Tumor,greater,than,3,cm,,,but,5,cm,or,less,in,greatest,dimension,surrounded,by,lung,or,visceral,pleura,without,bronchoscopic,evidence,of,invasion,more,proximal,than,the,lobar,bronchus,(,i.e.,,,not,in,the,main,bronchus,),;,or,Tumor,5,cm,or,less,in,greatest,dimension,with,any,of,the,following,features,of,extent,:,involves,main,bronchus,,,2,cm,or,more,distal,to,the,carina,;,invades,the,visceral,pleura,;,associated,with,atelectasis,or,obstructive,pneumonitis,that,extends,to,the,hilar,region,but,does,not,inolve,the,entire,lung,Regional,Lymph,Nodes,(,pN,),pNo,:,No,regional,lymph,node,metastasis,Number,Examined,32,Number,Involved,o,Distant,Metastases,(,pM,),:,Not,applicable}","{lung,:,Resection,SPECIMEN,Specimen,:,lung,procedure,:,Lobectomy,Specimen,Integrity,:,Intact,Specimen,Laterality,:,Right,tumor,site,:,Upper,lobe,tumor,focality,:,unifocal,tumor,histologic,type,:,adenocarcinoma,histologic,Grade,:,g2,:,moderately,differentiate,EXTENT,tumor,size,:,greatest,dimension,(,cm,),3.5,cm,visceral,Pleura,Invasion,:,not,identify,margin,bronchial,margin,bronchial,margin,involvement,by,Invasive,Carcinoma,:,uninvolved,by,invasive,carcinoma,vascular,margin,:,uninvolve,by,invasive,carcinoma,accessory,finding,lymph-vascular,Invasion,:,not,identify,stage,(,ptnm,),primary,tumor,(,pt,),:,pt2a,:,tumor,greater,than,3,cm,,,but,5,cm,or,less,in,greatest,dimension,surround,by,lung,or,visceral,pleuron,without,bronchoscopic,evidence,of,invasion,more,proximal,than,the,lobar,bronchus,(,i.e.,,,not,in,the,main,bronchus,),;,or,tumor,5,cm,or,less,in,greatest,dimension,with,any,of,the,follow,feature,of,extent,:,involve,main,bronchus,,,2,cm,or,more,distal,to,the,carina,;,invade,the,visceral,pleuron,;,associate,with,atelectasis,or,obstructive,pneumonitis,that,extend,to,the,hilar,region,but,do,not,inolve,the,entire,lung,Regional,Lymph,Nodes,(,pn,),pno,:,no,regional,lymph,node,metastasis,number,examine,32,Number,involve,o,distant,metastase,(,pm,),:,not,applicable}","{NN,:,NNP,NNP,NNP,:,NN,NN,:,NNP,NNP,NNP,:,NNP,NNP,NNP,:,NNP,NN,NN,:,NNP,NN,NN,NN,:,JJ,NN,JJ,NN,:,NN,JJ,NNP,:,NN,:,RB,VBN,NNP,NN,NN,:,JJS,NN,CD,NN,NN,CD,NN,JJ,NNP,NNP,:,RB,VBN,NNS,JJ,NN,JJ,NN,NN,IN,NNP,NNP,:,JJ,IN,JJ,NN,JJ,NN,:,VBN,IN,JJ,NN,NN,NNS,JJ,NNP,:,RB,VBN,NN,CD,NN,CD,JJ,NN,CD,NN,CD,:,NN,:,NN,JJR,IN,CD,NN,,,CC,CD,NN,CC,JJR,IN,JJS,NN,VBN,IN,NN,CC,JJ,NN,IN,JJ,NN,IN,NN,RBR,JJ,IN,DT,JJ,NN,CD,FW,,,RB,IN,DT,JJ,NN,NN,:,CC,NN,CD,NN,CC,JJR,IN,JJS,NN,IN,DT,IN,DT,VBG,NNS,IN,NN,:,VBZ,JJ,NNS,,,CD,NN,CC,JJR,JJ,TO,DT,NN,:,VBZ,DT,JJ,NN,:,VBN,IN,NN,CC,JJ,NN,WDT,VBZ,TO,DT,JJ,NN,CC,VBZ,RB,VB,DT,JJ,NN,NNP,NNP,NNP,CD,NN,CD,NN,:,DT,JJ,NN,NN,NN,NN,VBN,CD,NNP,VBN,NN,JJ,NNS,VBP,NN,CD,:,RB,JJ}","{219,0,219,219,219,0,219,219,0,219,219,219,0,219,219,219,0,219,219,219,0,219,219,219,219,0,219,219,219,219,0,219,219,219,0,219,0,219,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,219,0,219,219,219,219,219,219,0,219,219,219,219,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,219,0,219,0,219,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,0,219,219,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,0,219,219,219,0,219,219,219,219,219,219,219,219,0,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,0,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,219,0,219,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_27,"Pathologist","{Pathologist}","{pathologist}","{NN}","{0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_28,"CLINICAL HISTORY AND PRE ? OPERATIVE DIAGNOSIS : jwith hX of breast cancer , now with a RUL adenocarcinoma .","{CLINICAL,HISTORY,AND,PRE,?,OPERATIVE,DIAGNOSIS,:,jwith,hX,of,breast,cancer,,,now,with,a,RUL,adenocarcinoma,.}","{clinical,history,and,pre,?,OPERATIVE,DIAGNOSIS,:,jwith,hx,of,breast,cancer,,,now,with,a,rul,adenocarcinoma,.}","{JJ,NN,CC,NN,CD,NNP,NNP,:,NN,NN,IN,NN,NN,,,RB,IN,DT,NN,NN,.}","{2,0,0,7,7,7,2,0,10,2,0,13,10,0,2,0,19,19,2,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_29,"MACROSCOPIC DESCRIPTION : The specimen is received in five parts , each labeled with the patient ? s name .","{MACROSCOPIC,DESCRIPTION,:,The,specimen,is,received,in,five,parts,,,each,labeled,with,the,patient,?,s,name,.}","{macroscopic,description,:,the,specimen,be,receive,in,five,part,,,each,label,with,the,patient,?,s,name,.}","{JJ,NN,:,DT,NN,VBZ,VBN,IN,CD,NNS,,,DT,VBN,IN,DT,NN,CD,NNS,NN,.}","{2,0,0,5,7,7,2,0,10,7,0,7,12,0,16,13,18,16,18,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_30,"1 .","{1,.}","{1,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_31,"Part one is labeled ? lung , right upper lobe ? .","{Part,one,is,labeled,?,lung,,,right,upper,lobe,?,.}","{Part,one,be,label,?,lung,,,right,upper,lobe,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,,,JJ,JJ,NN,NN,.}","{4,1,4,0,6,4,0,11,11,11,6,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_32,"It consists of a right lobe of lung , measuring 15.5 X 10.5 X 4 cm .","{It,consists,of,a,right,lobe,of,lung,,,measuring,15.5,X,10.5,X,4,cm,.}","{it,consist,of,a,right,lobe,of,lung,,,measure,15.5,x,10.5,x,4,cm,.}","{PRP,VBZ,IN,DT,JJ,NN,IN,NN,,,VBG,CD,NN,CD,NN,CD,NN,.}","{2,0,0,6,6,2,0,6,0,2,12,14,14,10,16,14,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_33,"The two staple lines measures 6 cm and 5.5 cm which is shaved and the pleura around the staple line is inked in black .","{The,two,staple,lines,measures,6,cm,and,5.5,cm,which,is,shaved,and,the,pleura,around,the,staple,line,is,inked,in,black,.}","{the,two,staple,line,measure,6,cm,and,5.5,cm,which,be,shave,and,the,pleuron,around,the,staple,line,be,ink,in,black,.}","{DT,CD,NN,NNS,VBZ,CD,NN,CC,CD,NN,WDT,VBZ,VBN,CC,DT,NN,IN,DT,NN,NN,VBZ,VBN,IN,JJ,.}","{4,4,4,5,0,7,5,0,10,5,13,13,10,0,16,22,0,20,20,16,22,5,0,22,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_34,"The bronchial margin at the hilum area measures 2 cm and the Vascular margin measures 1.2 cm .","{The,bronchial,margin,at,the,hilum,area,measures,2,cm,and,the,Vascular,margin,measures,1.2,cm,.}","{the,bronchial,margin,at,the,hilum,area,measure,2,cm,and,the,vascular,margin,measure,1.2,cm,.}","{DT,JJ,NN,IN,DT,NN,NN,NNS,CD,NN,CC,DT,JJ,NN,NNS,CD,NN,.}","{3,3,0,0,8,8,8,3,10,3,0,15,15,15,3,17,15,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_35,"The pleura are gray pink glistening and mottled moderately with fine black streaks .","{The,pleura,are,gray,pink,glistening,and,mottled,moderately,with,fine,black,streaks,.}","{the,pleuron,be,gray,pink,glistening,and,mottled,moderately,with,fine,black,streak,.}","{DT,NN,VBP,JJ,JJ,NN,CC,JJ,RB,IN,JJ,JJ,NNS,.}","{2,6,6,5,6,0,0,13,13,0,9,13,6,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_36,"There is a puckered area measuring 2.5 cm in greatest dimension .","{There,is,a,puckered,area,measuring,2.5,cm,in,greatest,dimension,.}","{there,be,a,puckered,area,measure,2.5,cm,in,greatest,dimension,.}","{EX,VBZ,DT,JJ,NN,VBG,CD,NN,IN,JJS,NN,.}","{2,0,5,5,2,5,8,6,0,11,8,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_37,"Beneath the puckered area there is a gray white finn nodule with ill defined borders measuring 3.5 X 3 X 2 cm , located 3 cm from the bronchial resection margin , and 2 cm from the closest staple line margin .","{Beneath,the,puckered,area,there,is,a,gray,white,finn,nodule,with,ill,defined,borders,measuring,3.5,X,3,X,2,cm,,,located,3,cm,from,the,bronchial,resection,margin,,,and,2,cm,from,the,closest,staple,line,margin,.}","{beneath,the,puckered,area,there,be,a,gray,white,finn,nodule,with,ill,define,border,measure,3.5,x,3,x,2,cm,,,located,3,cm,from,the,bronchial,resection,margin,,,and,2,cm,from,the,closest,staple,line,margin,.}","{IN,DT,JJ,NN,EX,VBZ,DT,JJ,JJ,NN,NN,IN,JJ,VBN,NNS,VBG,CD,NN,CD,NN,CD,NN,,,JJ,CD,NN,IN,DT,JJ,NN,NN,,,CC,CD,NN,IN,DT,JJS,JJ,NN,NN,.}","{0,4,4,6,6,0,11,11,11,11,6,0,11,13,14,14,18,16,22,22,20,18,0,26,24,18,0,31,31,31,26,0,0,35,18,0,41,39,41,41,35,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_38,"The remainder of the parenchyma is red and blotchy .","{The,remainder,of,the,parenchyma,is,red,and,blotchy,.}","{the,remainder,of,the,parenchyma,be,red,and,blotchy,.}","{DT,NN,IN,DT,NN,VBZ,JJ,CC,JJ,.}","{2,9,0,5,2,7,0,0,7,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_39,"No other nodule grossly identified .","{No,other,nodule,grossly,identified,.}","{no,other,nodule,grossly,identify,.}","{DT,JJ,NN,RB,VBN,.}","{3,3,0,5,3,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_40,"Multiple anthracotic firm lymph nodes ranging from 0.3 cm to 0.6 cm identified from the hilar and peribronchial area .","{Multiple,anthracotic,firm,lymph,nodes,ranging,from,0.3,cm,to,0.6,cm,identified,from,the,hilar,and,peribronchial,area,.}","{multiple,anthracotic,firm,lymph,node,range,from,0.3,cm,to,0.6,cm,identify,from,the,hilar,and,peribronchial,area,.}","{JJ,JJ,NN,NN,NNS,VBG,IN,CD,NN,TO,CD,NN,VBN,IN,DT,JJ,CC,JJ,NN,.}","{5,5,5,5,13,5,0,9,6,0,12,6,0,0,19,19,0,16,13,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_41,"Representative sections are submitted .","{Representative,sections,are,submitted,.}","{Representative,section,be,submit,.}","{NNP,NNS,VBP,VBN,.}","{2,4,4,0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_42,"2 .","{2,.}","{2,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_43,"Part two is labeled ? station 10 lymph node ? .","{Part,two,is,labeled,?,station,10,lymph,node,?,.}","{Part,two,be,label,?,station,10,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,.}","{4,1,4,0,10,10,10,10,10,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_44,"It consists of multiple soft red ? black lymph nodes measuring 2.4 X 2 X 0.5 cm in aggregate .","{It,consists,of,multiple,soft,red,?,black,lymph,nodes,measuring,2.4,X,2,X,0.5,cm,in,aggregate,.}","{it,consist,of,multiple,soft,red,?,black,lymph,node,measure,2.4,x,2,x,0.5,cm,in,aggregate,.}","{PRP,VBZ,IN,JJ,JJ,JJ,NN,JJ,NN,NNS,VBG,CD,NN,CD,NN,CD,NN,IN,NN,.}","{2,0,0,7,7,7,2,10,10,2,10,13,11,15,13,17,11,0,17,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_45,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_46,"3 .","{3,.}","{3,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_47,"Part three is labeled ? station 11 lymph node ? .","{Part,three,is,labeled,?,station,11,lymph,node,?,.}","{Part,three,be,label,?,station,11,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,.}","{4,1,4,0,10,10,10,10,10,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_48,"It consists of multiple soft red ? black lymph nodes measuring 2 X 1.7 X 0.6 cm in aggregate .","{It,consists,of,multiple,soft,red,?,black,lymph,nodes,measuring,2,X,1.7,X,0.6,cm,in,aggregate,.}","{it,consist,of,multiple,soft,red,?,black,lymph,node,measure,2,x,1.7,x,0.6,cm,in,aggregate,.}","{PRP,VBZ,IN,JJ,JJ,JJ,NN,JJ,NN,NNS,VBG,CD,NN,CD,NN,CD,NN,IN,NN,.}","{2,0,0,7,7,7,2,10,10,2,10,13,11,15,13,17,11,0,17,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_49,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_50,"4 .","{4,.}","{4,.}","{LS,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_51,"Part four is labeled ? station 2 and 4 lymph node ? .","{Part,four,is,labeled,?,station,2,and,4,lymph,node,?,.}","{Part,four,be,label,?,station,2,and,4,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,CC,CD,NN,NN,NN,.}","{4,1,4,0,6,4,6,0,12,12,12,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_52,"It consists of multiple soft red ? black lymph nodes measuring 0.5 cm to 0.8 cm .","{It,consists,of,multiple,soft,red,?,black,lymph,nodes,measuring,0.5,cm,to,0.8,cm,.}","{it,consist,of,multiple,soft,red,?,black,lymph,node,measure,0.5,cm,to,0.8,cm,.}","{PRP,VBZ,IN,JJ,JJ,JJ,NN,JJ,NN,NNS,VBG,CD,NN,TO,CD,NN,.}","{2,0,0,7,7,7,2,10,10,2,10,13,11,0,16,11,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_53,"Entirely submitted in three cassettes .","{Entirely,submitted,in,three,cassettes,.}","{entirely,submit,in,three,cassette,.}","{RB,VBN,IN,CD,NNS,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_54,"5 .","{5,.}","{5,.}","{CD,.}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_55,"Part five is labeled ? station 7 lymph node ? .","{Part,five,is,labeled,?,station,7,lymph,node,?,.}","{Part,five,be,label,?,station,7,lymph,node,?,.}","{NNP,CD,VBZ,VBN,JJ,NN,CD,NN,NN,NN,.}","{4,1,4,0,10,10,10,10,10,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_56,"It consists of multiple soft red ? black lymph nodes measuring 2.4 X 1.5 X 0.5 cm in aggregate .","{It,consists,of,multiple,soft,red,?,black,lymph,nodes,measuring,2.4,X,1.5,X,0.5,cm,in,aggregate,.}","{it,consist,of,multiple,soft,red,?,black,lymph,node,measure,2.4,x,1.5,x,0.5,cm,in,aggregate,.}","{PRP,VBZ,IN,JJ,JJ,JJ,NN,JJ,NN,NNS,VBG,CD,NN,CD,NN,CD,NN,IN,NN,.}","{2,0,0,7,7,7,2,10,10,2,10,13,17,17,17,15,11,0,17,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_57,"Entirely submitted in one cassette .","{Entirely,submitted,in,one,cassette,.}","{entirely,submit,in,one,cassette,.}","{RB,VBN,IN,CD,NN,.}","{2,0,0,5,2,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_58,"SUMMARY OF SECTIONS : lA ? lE nodule lF staple line margin lG bronchial margin , shaved lH vascular margin , shaved ll anthracotic lymph node lJ random section 2A entirely submitted 3A entirely submitted 4A ? 4C entirely submitted 5A entirely submitted","{SUMMARY,OF,SECTIONS,:,lA,?,lE,nodule,lF,staple,line,margin,lG,bronchial,margin,,,shaved,lH,vascular,margin,,,shaved,ll,anthracotic,lymph,node,lJ,random,section,2A,entirely,submitted,3A,entirely,submitted,4A,?,4C,entirely,submitted,5A,entirely,submitted}","{summary,of,section,:,la,?,le,nodule,lf,staple,line,margin,lg,bronchial,margin,,,shave,lh,vascular,margin,,,shave,ll,anthracotic,lymph,node,lj,random,section,2a,entirely,submit,3a,entirely,submit,4a,?,4c,entirely,submit,5a,entirely,submit}","{NN,IN,NNS,:,NN,CD,NN,NN,NN,NN,NN,NN,NN,JJ,NN,,,VBD,NN,JJ,NN,,,VBD,NN,JJ,NN,NN,NN,JJ,NN,NN,RB,VBD,NN,RB,VBD,NN,CD,NN,RB,VBD,NN,RB,VBD}","{17,0,1,0,8,8,8,1,15,15,15,15,15,15,8,0,0,20,20,17,0,20,22,27,27,27,22,30,30,32,32,27,35,35,32,40,38,39,40,35,43,43,40}","{}"
TCGA-97-8172, TCGA-97-8172SENT_59,"SPECIAL PROCEDURES : Elastic","{SPECIAL,PROCEDURES,:,Elastic}","{special,procedure,:,elastic}","{JJ,NNS,:,JJ}","{2,0,0,2}","{}"
TCGA-97-8172, TCGA-97-8172SENT_60,"Final Dia nosis erfonned by","{Final,Dia,nosis,erfonned,by}","{final,dium,nosis,erfonn,by}","{JJ,NN,NN,VBN,IN}","{3,3,4,0,4}","{}"
TCGA-97-8172, TCGA-97-8172SENT_61,"Electronically","{Electronically}","{electronically}","{RB}","{0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_62,"ADDENDUM # 1 FOR MOLECULAR TESTS :","{ADDENDUM,#,1,FOR,MOLECULAR,TESTS,:}","{ADDENDUM,#,1,for,molecular,test,:}","{NNP,#,CD,IN,NN,NNS,:}","{0,3,1,0,6,3,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_63,"KRAS , EGFR and ALK were sent on ? for patient","{KRAS,,,EGFR,and,ALK,were,sent,on,?,for,patient}","{KRAS,,,egfr,and,alk,be,send,on,?,for,patient}","{NNP,,,NN,CC,NN,VBD,VBN,IN,NN,IN,NN}","{7,0,1,0,1,7,0,0,7,0,9}","{}"
TCGA-97-8172, TCGA-97-8172SENT_64,"The test is to be perfonned on tissue from case","{The,test,is,to,be,perfonned,on,tissue,from,case}","{the,test,be,to,be,perfonn,on,tissue,from,case}","{DT,NN,VBZ,TO,VB,VBN,IN,NN,IN,NN}","{2,3,0,6,6,3,0,6,0,6}","{}"
TCGA-97-8172, TCGA-97-8172SENT_65,"The case report , slides , and blocks for the cited accession number were retrieved from archives .","{The,case,report,,,slides,,,and,blocks,for,the,cited,accession,number,were,retrieved,from,archives,.}","{the,case,report,,,slide,,,and,block,for,the,cite,accession,number,be,retrieve,from,archive,.}","{DT,NN,NN,,,NNS,,,CC,VBZ,IN,DT,VBN,NN,NN,VBD,VBN,IN,NNS,.}","{3,3,8,0,3,0,8,0,15,13,13,13,15,15,8,0,15,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_66,"The pathologist whose signature appears below reviewed the original pathology report , examined candidate H&E slides , and selected block lB appropriate to the specifications of the ordered molecular analysis .","{The,pathologist,whose,signature,appears,below,reviewed,the,original,pathology,report,,,examined,candidate,H&E,slides,,,and,selected,block,lB,appropriate,to,the,specifications,of,the,ordered,molecular,analysis,.}","{the,pathologist,whose,signature,appear,below,review,the,original,pathology,report,,,examine,candidate,h&e,slide,,,and,select,block,lb,appropriate,to,the,specification,of,the,order,molecular,analysis,.}","{DT,NN,WP$,NN,VBZ,IN,VBN,DT,JJ,NN,NN,,,VBN,NN,NN,NNS,,,CC,VBN,NN,NN,JJ,TO,DT,NNS,IN,DT,VBN,JJ,NN,.}","{2,0,4,5,2,5,2,11,11,11,7,0,2,16,16,13,0,0,7,21,22,19,0,25,22,0,30,30,30,25,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_67,"Xl H&E and X9 unstained slides were prepared and forwarded to - where the subject molecular test will be performed .","{Xl,H&E,and,X9,unstained,slides,were,prepared,and,forwarded,to,-,where,the,subject,molecular,test,will,be,performed,.}","{xl,h&e,and,x9,unstained,slide,be,prepare,and,forward,to,-,where,the,subject,molecular,test,will,be,perform,.}","{NN,NN,CC,NN,JJ,NNS,VBD,VBN,CC,VBN,TO,:,WRB,DT,JJ,JJ,NN,MD,VB,VBN,.}","{2,10,0,6,6,2,8,0,0,8,10,0,20,17,17,17,20,20,20,10,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_68,"An addendum report will be issued when the results of this molecular test are available .","{An,addendum,report,will,be,issued,when,the,results,of,this,molecular,test,are,available,.}","{a,addendum,report,will,be,issue,when,the,result,of,this,molecular,test,be,available,.}","{DT,NN,NN,MD,VB,VBN,WRB,DT,NNS,IN,DT,JJ,NN,VBP,JJ,.}","{3,3,6,6,6,0,15,9,15,0,13,13,9,15,6,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_69,"Addendum # 1 erformed by","{Addendum,#,1,erformed,by}","{Addendum,#,1,erform,by}","{NNP,#,CD,VBN,IN}","{0,3,1,1,4}","{}"
TCGA-97-8172, TCGA-97-8172SENT_70,"Electronically signed ?","{Electronically,signed,?}","{electronically,sign,?}","{RB,VBN,NN}","{2,0,2}","{}"
TCGA-97-8172, TCGA-97-8172SENT_71,"ADDENDUM # 2 :","{ADDENDUM,#,2,:}","{ADDENDUM,#,2,:}","{NNP,#,CD,:}","{0,3,1,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_72,"MOLECULAR ONCOLOGY","{MOLECULAR,ONCOLOGY}","{molecular,oncology}","{JJ,NN}","{2,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_73,"KRAS MUTATION ANALYSIS","{KRAS,MUTATION,ANALYSIS}","{KRAS,MUTATION,ANALYSIS}","{NNP,NNP,NNP}","{3,3,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_74,"Referring Physician Body Site : Right upper lobe of lung Specimen Type : Slides Clinical Data : Adenocarcinoma","{Referring,Physician,Body,Site,:,Right,upper,lobe,of,lung,Specimen,Type,:,Slides,Clinical,Data,:,Adenocarcinoma}","{refer,physician,body,site,:,Right,upper,lobe,of,lung,specimen,type,:,slide,clinical,datum,:,adenocarcinoma}","{VBG,NN,NN,NN,:,NNP,JJ,NN,IN,NN,NN,NN,:,NNS,JJ,NNS,:,NN}","{0,1,4,2,0,8,8,2,0,12,12,8,0,2,16,14,0,2}","{}"
TCGA-97-8172, TCGA-97-8172SENT_75,"RESULTS : Positive for a p. Gl2V ( c. 35G > T ) mutation in codon 12 of the KRAS gene .","{RESULTS,:,Positive,for,a,p.,Gl2V,(,c.,35G,>,T,),mutation,in,codon,12,of,the,KRAS,gene,.}","{result,:,positive,for,a,p.,gl2v,(,c.,35g,>,t,),mutation,in,codon,12,of,the,KRAS,gene,.}","{NNS,:,JJ,IN,DT,NN,NN,CD,NN,NN,JJR,NN,NN,NN,IN,NN,CD,IN,DT,NNP,NN,.}","{0,0,1,0,10,10,10,10,10,3,14,14,14,10,0,14,16,0,21,21,16,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_76,"INTERPRETATION : Mutations in the KRAS gene are reported to correlate with poor prognosis and resistance to tyrosine kinase inhibitor therapies in patients with non ? small ? cell lung cancer .","{INTERPRETATION,:,Mutations,in,the,KRAS,gene,are,reported,to,correlate,with,poor,prognosis,and,resistance,to,tyrosine,kinase,inhibitor,therapies,in,patients,with,non,?,small,?,cell,lung,cancer,.}","{interpretation,:,mutation,in,the,KRAS,gene,be,report,to,correlate,with,poor,prognosis,and,resistance,to,tyrosine,kinase,inhibitor,therapy,in,patient,with,non,?,small,?,cell,lung,cancer,.}","{NN,:,NNS,IN,DT,NNP,NN,VBP,VBN,TO,VB,IN,JJ,NN,CC,NN,TO,NN,NN,NN,NNS,IN,NNS,IN,JJ,JJ,JJ,NN,NN,NN,NN,.}","{0,0,9,0,7,7,3,9,1,11,9,0,14,11,0,14,0,21,21,21,11,0,11,0,31,31,31,31,31,31,23,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_77,"COMMENT : KRAS mutations occur in 15-30 % of non ? small ? cell lung cancer ( NSCLC ) patients and are strongly associated with adenocarcinoma and smoking history .","{COMMENT,:,KRAS,mutations,occur,in,15-30,%,of,non,?,small,?,cell,lung,cancer,(,NSCLC,),patients,and,are,strongly,associated,with,adenocarcinoma,and,smoking,history,.}","{COMMENT,:,KRAS,mutation,occur,in,15-30,%,of,non,?,small,?,cell,lung,cancer,(,nsclc,),patient,and,be,strongly,associate,with,adenocarcinoma,and,smoking,history,.}","{NNP,:,NNP,NNS,VBP,IN,CD,NN,IN,JJ,JJ,JJ,NN,NN,NN,NN,CD,NN,CD,NNS,CC,VBP,RB,VBN,IN,NN,CC,NN,NN,.}","{0,0,4,5,1,0,8,5,0,18,18,18,18,18,18,18,18,8,20,5,0,24,24,5,0,29,0,29,24,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_78,"This assay analyzes codons l2 and 13 in exon 2 of the KRAS gene ; based on the current literature , approximately 98 % of mutations are expected to occur in these codons .","{This,assay,analyzes,codons,l2,and,13,in,exon,2,of,the,KRAS,gene,;,based,on,the,current,literature,,,approximately,98,%,of,mutations,are,expected,to,occur,in,these,codons,.}","{this,assay,analyze,codon,l2,and,13,in,exon,2,of,the,KRAS,gene,;,base,on,the,current,literature,,,approximately,98,%,of,mutation,be,expect,to,occur,in,these,codon,.}","{DT,NN,VBZ,NNS,NN,CC,CD,IN,NN,CD,IN,DT,NNP,NN,:,VBN,IN,DT,JJ,NN,,,RB,CD,NN,IN,NNS,VBP,VBN,TO,VB,IN,DT,NNS,.}","{2,3,0,5,3,0,5,0,3,9,0,14,14,9,0,0,28,20,20,28,0,23,24,28,0,24,28,3,30,28,0,33,30,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_79,"The analytical sensitivity of the assay is approximately 10 % ; thus mutations present in a low percentage of cells may not be detected .","{The,analytical,sensitivity,of,the,assay,is,approximately,10,%,;,thus,mutations,present,in,a,low,percentage,of,cells,may,not,be,detected,.}","{the,analytical,sensitivity,of,the,assay,be,approximately,10,%,;,thus,mutation,present,in,a,low,percentage,of,cell,may,not,be,detect,.}","{DT,JJ,NN,IN,DT,NN,VBZ,RB,CD,NN,:,RB,NNS,JJ,IN,DT,JJ,NN,IN,NNS,MD,RB,VB,VBN,.}","{3,3,10,0,6,3,10,9,10,0,0,24,24,13,0,18,18,14,0,18,24,24,24,10,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_80,"This test is validated for use in identifying KRAS codon 12 and codon 13 mutations in fresh , frozen , or formalin ? fixed paraffin embedded tissue .","{This,test,is,validated,for,use,in,identifying,KRAS,codon,12,and,codon,13,mutations,in,fresh,,,frozen,,,or,formalin,?,fixed,paraffin,embedded,tissue,.}","{this,test,be,validate,for,use,in,identify,KRAS,codon,12,and,codon,13,mutation,in,fresh,,,frozen,,,or,formalin,?,fix,paraffin,embedded,tissue,.}","{DT,NN,VBZ,VBN,IN,NN,IN,VBG,NNP,NN,CD,CC,NN,CD,NNS,IN,JJ,,,JJ,,,CC,NN,CD,VBN,NN,JJ,NN,.}","{2,4,4,0,0,4,0,6,10,8,10,0,10,15,13,0,8,0,8,0,0,8,22,6,27,27,24,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_81,"In particular the test performance has been established in samples of colorectal cancer and non ? small cell lung carcinoma which harbor these mutations , although several other tissues are also known to harbor KRAS mutations ( e. g. tumors of pancreas , bile duct , ovary , appendix , etc. ) .","{In,particular,the,test,performance,has,been,established,in,samples,of,colorectal,cancer,and,non,?,small,cell,lung,carcinoma,which,harbor,these,mutations,,,although,several,other,tissues,are,also,known,to,harbor,KRAS,mutations,(,e.,g.,tumors,of,pancreas,,,bile,duct,,,ovary,,,appendix,,,etc.,),.}","{in,particular,the,test,performance,have,be,establish,in,sample,of,colorectal,cancer,and,non,?,small,cell,lung,carcinoma,which,harbor,these,mutation,,,although,several,other,tissue,be,also,know,to,harbor,KRAS,mutation,(,e.,g.,tumor,of,pancreas,,,bile,duct,,,ovary,,,appendix,,,etc.,),.}","{IN,JJ,DT,NN,NN,VBZ,VBN,VBN,IN,NNS,IN,JJ,NN,CC,JJ,JJ,JJ,NN,NN,NN,WDT,VBP,DT,NNS,,,IN,JJ,JJ,NNS,VBP,RB,VBN,TO,VB,NNP,NNS,CD,NN,NN,NNS,IN,NN,,,NN,NN,,,NN,,,NN,,,FW,FW,.}","{0,8,5,5,8,8,8,0,0,8,0,13,10,0,20,20,20,20,20,10,22,20,24,22,0,32,29,29,32,32,32,8,34,32,36,40,40,40,40,34,0,40,0,45,42,0,42,0,42,0,52,42,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_82,"METHOD/LIMITATIONS : Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis .","{METHOD/LIMITATIONS,:,Tissue,sections,are,reviewed,by,a,pathologist,and,relevant,tumor,is,selected,for,analysis,.}","{METHOD/LIMITATIONS,:,tissue,section,be,review,by,a,pathologist,and,relevant,tumor,be,select,for,analysis,.}","{NNP,:,NN,NNS,VBP,VBN,IN,DT,NN,CC,JJ,NN,VBZ,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,0,12,14,14,6,0,14,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_83,"DNA is isolated from the sample , quantified and amplified by polymerase chain reaction ( PCR ) using primers to exon 2 of the KRAS gene .","{DNA,is,isolated,from,the,sample,,,quantified,and,amplified,by,polymerase,chain,reaction,(,PCR,),using,primers,to,exon,2,of,the,KRAS,gene,.}","{dna,be,isolate,from,the,sample,,,quantify,and,amplify,by,polymerase,chain,reaction,(,pcr,),use,primer,to,exon,2,of,the,KRAS,gene,.}","{NN,VBZ,VBN,IN,DT,NN,,,VBN,CC,VBN,IN,NN,NN,NN,CD,NN,NN,VBG,NNS,TO,NN,CD,IN,DT,NNP,NN,.}","{10,3,0,0,6,3,0,3,0,3,0,17,17,17,17,17,10,17,18,0,18,21,0,26,26,21,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_84,"PCR products are subjected to single nucleotide primer extension to detect mutations at codons 12 and 13 ; primer extension products are analyzed using capillary gel electrophoresis and ?uorescence detection .","{PCR,products,are,subjected,to,single,nucleotide,primer,extension,to,detect,mutations,at,codons,12,and,13,;,primer,extension,products,are,analyzed,using,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{pcr,product,be,subject,to,single,nucleotide,primer,extension,to,detect,mutation,at,codon,12,and,13,;,primer,extension,product,be,analyze,use,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{NN,NNS,VBP,VBN,TO,JJ,NN,NN,NN,TO,VB,NNS,IN,NNS,CD,CC,CD,:,NN,NN,NNS,VBP,VBN,VBG,JJ,NN,NN,CC,NN,NN,.}","{2,4,4,0,0,9,9,9,4,11,4,11,0,11,14,0,11,0,21,21,23,23,4,23,27,27,24,0,30,27,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_85,"False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample .","{False,positive,or,negative,results,may,occur,for,reasons,that,include,genetic,variants,or,somatic,heterogeneity,of,the,tissue,sample,.}","{false,positive,or,negative,result,may,occur,for,reason,that,include,genetic,variant,or,somatic,heterogeneity,of,the,tissue,sample,.}","{JJ,JJ,CC,JJ,NNS,MD,VB,IN,NNS,WDT,VBP,JJ,NNS,CC,JJ,NN,IN,DT,NN,NN,.}","{5,5,0,2,7,7,0,0,7,11,9,13,11,0,16,13,0,20,20,16,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_86,"REFERENCES :","{REFERENCES,:}","{reference,:}","{NNS,:}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_87,"This test was develo ed and its erfonnance characteristics detennined b The laboratory is re ulated under the Clinical Laboratory Improvement Amendments of h as qualified to perfonn high complexity clinical testing .","{This,test,was,develo,ed,and,its,erfonnance,characteristics,detennined,b,The,laboratory,is,re,ulated,under,the,Clinical,Laboratory,Improvement,Amendments,of,h,as,qualified,to,perfonn,high,complexity,clinical,testing,.}","{this,test,be,develo,ed,and,its,erfonnance,characteristic,detennine,b,the,laboratory,be,re,ulate,under,the,clinical,laboratory,improvement,amendment,of,h,as,qualify,to,perfonn,high,complexity,clinical,testing,.}","{DT,NN,VBD,JJ,NN,CC,PRP$,NN,NNS,VBD,NN,DT,NN,VBZ,JJ,VBN,IN,DT,JJ,NN,NN,NNS,IN,NN,IN,VBN,TO,VB,JJ,NN,JJ,NN,.}","{2,5,5,5,0,0,9,9,10,5,10,13,15,15,11,15,0,20,20,16,22,16,0,22,0,32,28,26,30,28,32,16,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_88,"This particular test is not considered a stand along test and should be used only in the context of other diagnostic tests or clinical work ? up related to treatment decisions .","{This,particular,test,is,not,considered,a,stand,along,test,and,should,be,used,only,in,the,context,of,other,diagnostic,tests,or,clinical,work,?,up,related,to,treatment,decisions,.}","{this,particular,test,be,not,consider,a,stand,along,test,and,should,be,use,only,in,the,context,of,other,diagnostic,test,or,clinical,work,?,up,related,to,treatment,decision,.}","{DT,JJ,NN,VBZ,RB,VBN,DT,NN,IN,NN,CC,MD,VB,VBN,RB,IN,DT,NN,IN,JJ,JJ,NNS,CC,JJ,NN,RB,RB,JJ,TO,NN,NNS,.}","{3,3,14,6,6,0,8,6,0,8,0,14,14,6,14,0,18,14,0,22,22,18,0,25,27,25,28,6,0,31,28,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_89,"Electronicall si ned by :","{Electronicall,si,ned,by,:}","{Electronicall,si,ned,by,:}","{NNP,FW,FW,IN,:}","{0,3,1,3,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_90,"Addendum # 2 ierformed by Electronically signed","{Addendum,#,2,ierformed,by,Electronically,signed}","{Addendum,#,2,ierform,by,electronically,sign}","{NNP,#,CD,VBN,IN,RB,VBN}","{0,3,7,3,4,5,1}","{}"
TCGA-97-8172, TCGA-97-8172SENT_91,"ADDENDUM # 3 :","{ADDENDUM,#,3,:}","{ADDENDUM,#,3,:}","{NNP,#,CD,:}","{0,3,1,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_92,"EGFR Mutation Analysis","{EGFR,Mutation,Analysis}","{egfr,mutation,analysis}","{NN,NN,NN}","{0,3,1}","{}"
TCGA-97-8172, TCGA-97-8172SENT_93,"Referring Physician : Body","{Referring,Physician,:,Body}","{refer,physician,:,body}","{VBG,NN,:,NN}","{0,1,0,2}","{}"
TCGA-97-8172, TCGA-97-8172SENT_94,"Site : Right upper lobe of lung","{Site,:,Right,upper,lobe,of,lung}","{site,:,Right,upper,lobe,of,lung}","{NN,:,NNP,JJ,NN,IN,NN}","{0,0,5,5,1,0,5}","{}"
TCGA-97-8172, TCGA-97-8172SENT_95,"Clinical Data : Adenocarcinoma","{Clinical,Data,:,Adenocarcinoma}","{clinical,datum,:,adenocarcinoma}","{JJ,NNS,:,NN}","{2,0,0,2}","{}"
TCGA-97-8172, TCGA-97-8172SENT_96,"RESULTS : No mutation detected .","{RESULTS,:,No,mutation,detected,.}","{result,:,no,mutation,detect,.}","{NNS,:,DT,NN,VBN,.}","{0,0,4,1,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_97,"INTERPRETATION : No mutations were identified in the sample provided for analysis .","{INTERPRETATION,:,No,mutations,were,identified,in,the,sample,provided,for,analysis,.}","{interpretation,:,no,mutation,be,identify,in,the,sample,provide,for,analysis,.}","{NN,:,DT,NNS,VBD,VBN,IN,DT,NN,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,9,0,10,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_98,"Fewer than 5 % of non ? small cell lung carcinoma patients without identifiable mutations are reported to be responsive to EGFR tyrosine kinase inhibitor therapies .","{Fewer,than,5,%,of,non,?,small,cell,lung,carcinoma,patients,without,identifiable,mutations,are,reported,to,be,responsive,to,EGFR,tyrosine,kinase,inhibitor,therapies,.}","{fewer,than,5,%,of,non,?,small,cell,lung,carcinoma,patient,without,identifiable,mutation,be,report,to,be,responsive,to,egfr,tyrosine,kinase,inhibitor,therapy,.}","{JJR,IN,CD,NN,IN,JJ,JJ,JJ,NN,NN,NN,NNS,IN,JJ,NNS,VBP,VBN,TO,VB,JJ,TO,NN,NN,NN,NN,NNS,.}","{17,0,4,1,0,12,12,12,12,12,12,4,0,15,12,17,0,20,20,17,0,26,26,26,26,20,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_99,"COMMENT : Forty percent ( 40 % ) or more tumor cellularity is optimal for this mutation analysis .","{COMMENT,:,Forty,percent,(,40,%,),or,more,tumor,cellularity,is,optimal,for,this,mutation,analysis,.}","{COMMENT,:,forty,percent,(,40,%,),or,more,tumor,cellularity,be,optimal,for,this,mutation,analysis,.}","{NNP,:,CD,NN,CD,CD,NN,CD,CC,JJR,NN,NN,VBZ,JJ,IN,DT,NN,NN,.}","{0,0,4,14,7,7,4,4,0,4,12,8,14,1,0,18,18,14,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_100,"The sample submitted showed 4 % tumor cellularity upon pathologist review","{The,sample,submitted,showed,4,%,tumor,cellularity,upon,pathologist,review}","{the,sample,submit,show,4,%,tumor,cellularity,upon,pathologist,review}","{DT,NN,VBN,VBD,CD,NN,NN,NN,IN,NN,NN}","{2,4,2,0,6,8,8,4,0,11,4}","{}"
TCGA-97-8172, TCGA-97-8172SENT_101,"A frequently occurring sequence change 236lG > A ( Q787Q ) was identified .","{A,frequently,occurring,sequence,change,236lG,>,A,(,Q787Q,),was,identified,.}","{a,frequently,occur,sequence,change,236lg,>,a,(,q787q,),be,identify,.}","{DT,RB,VBG,NN,NN,NN,JJR,DT,CD,NN,NN,VBD,VBN,.}","{6,3,6,6,6,0,6,11,11,11,13,13,7,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_102,"This polymorphism is known not to have clinical significance .","{This,polymorphism,is,known,not,to,have,clinical,significance,.}","{this,polymorphism,be,know,not,to,have,clinical,significance,.}","{DT,NN,VBZ,VBN,RB,TO,VB,JJ,NN,.}","{2,4,4,0,7,7,4,9,7,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_103,"Mutations in the tyrosine domain of the epidennal growth factor receptor ( EGFR ) gene are reported to be associated with differential responsiveness or resistance to EGFR tyrosine kinase inhibitor ( TKI ) therapies .","{Mutations,in,the,tyrosine,domain,of,the,epidennal,growth,factor,receptor,(,EGFR,),gene,are,reported,to,be,associated,with,differential,responsiveness,or,resistance,to,EGFR,tyrosine,kinase,inhibitor,(,TKI,),therapies,.}","{mutation,in,the,tyrosine,domain,of,the,epidennal,growth,factor,receptor,(,egfr,),gene,be,report,to,be,associate,with,differential,responsiveness,or,resistance,to,egfr,tyrosine,kinase,inhibitor,(,tkus,),therapy,.}","{NNS,IN,DT,NN,NN,IN,DT,JJ,NN,NN,NN,CD,NN,NN,NN,VBP,VBN,TO,VB,VBN,IN,JJ,NN,CC,NN,TO,NN,NN,NN,NN,NN,NN,CD,NNS,.}","{17,0,5,5,1,0,11,11,11,11,5,15,15,15,11,17,0,20,20,17,0,23,20,0,23,0,32,32,32,32,32,20,34,32,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_104,"The objective response rate among patients with a sensitizing mutation ranges from 55 to 82 % .","{The,objective,response,rate,among,patients,with,a,sensitizing,mutation,ranges,from,55,to,82,%,.}","{the,objective,response,rate,among,patient,with,a,sensitize,mutation,range,from,55,to,82,%,.}","{DT,JJ,NN,NN,IN,NNS,IN,DT,VBG,NN,NNS,IN,CD,TO,CD,NN,.}","{4,4,4,0,0,4,0,11,11,11,6,0,15,15,16,11,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_105,"This assay analyzes exons 18-21 of the EGFR tyrosine kinase domain ; based on the current literature , most mutations in non ? small ? cell lung carcinoma ( NSCLC ) are expected to occur in these exons .","{This,assay,analyzes,exons,18-21,of,the,EGFR,tyrosine,kinase,domain,;,based,on,the,current,literature,,,most,mutations,in,non,?,small,?,cell,lung,carcinoma,(,NSCLC,),are,expected,to,occur,in,these,exons,.}","{this,assay,analyze,exon,18-21,of,the,egfr,tyrosine,kinase,domain,;,base,on,the,current,literature,,,most,mutation,in,non,?,small,?,cell,lung,carcinoma,(,nsclc,),be,expect,to,occur,in,these,exon,.}","{DT,NN,VBZ,NNS,CD,IN,DT,NN,NN,NN,NN,:,VBN,IN,DT,JJ,NN,,,JJS,NNS,IN,JJ,JJ,JJ,NN,NN,NN,NN,CD,NN,NN,VBP,VBN,TO,VB,IN,DT,NNS,.}","{2,3,0,3,4,0,11,11,11,11,4,0,0,33,17,17,33,0,20,17,0,28,28,28,28,28,28,20,31,31,33,33,3,35,33,0,38,35,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_106,"Mutations present in less than 10-20 % of extracted DNA may not be detected by this method .","{Mutations,present,in,less,than,10-20,%,of,extracted,DNA,may,not,be,detected,by,this,method,.}","{mutation,present,in,less,than,10-20,%,of,extract,dna,may,not,be,detect,by,this,method,.}","{NNS,JJ,IN,JJR,IN,CD,NN,IN,VBN,NN,MD,RB,VB,VBN,IN,DT,NN,.}","{14,1,0,5,6,7,2,0,10,7,14,14,14,0,0,17,14,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_107,"Mutation status in a sample may change during tumor progression or the course of therapy ; therefore , this result can not be used to infer the presence or absence of a mutation in another sample or sub ? sample obtained from this tumor .","{Mutation,status,in,a,sample,may,change,during,tumor,progression,or,the,course,of,therapy,;,therefore,,,this,result,can,not,be,used,to,infer,the,presence,or,absence,of,a,mutation,in,another,sample,or,sub,?,sample,obtained,from,this,tumor,.}","{mutation,status,in,a,sample,may,change,during,tumor,progression,or,the,course,of,therapy,;,therefore,,,this,result,can,not,be,use,to,infer,the,presence,or,absence,of,a,mutation,in,another,sample,or,sub,?,sample,obtain,from,this,tumor,.}","{NN,NN,IN,DT,NN,MD,VB,IN,NN,NN,CC,DT,NN,IN,NN,:,RB,,,DT,NN,MD,RB,VB,VBN,TO,VB,DT,NN,CC,NN,IN,DT,NN,IN,DT,NN,CC,NN,CD,NN,VBN,IN,DT,NN,.}","{2,7,0,5,2,7,0,0,10,7,0,13,10,0,13,0,24,0,20,24,24,24,24,7,26,24,28,26,0,28,0,33,28,0,36,33,0,40,40,33,40,0,44,41,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_108,"This test is validated for non ? small cell lung carcinoma .","{This,test,is,validated,for,non,?,small,cell,lung,carcinoma,.}","{this,test,be,validate,for,non,?,small,cell,lung,carcinoma,.}","{DT,NN,VBZ,VBN,IN,JJ,JJ,JJ,NN,NN,NN,.}","{2,4,4,0,0,11,11,11,11,11,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_109,"The clinical significance and utility of this test in other tumor types is unknown .","{The,clinical,significance,and,utility,of,this,test,in,other,tumor,types,is,unknown,.}","{the,clinical,significance,and,utility,of,this,test,in,other,tumor,type,be,unknown,.}","{DT,JJ,NN,CC,NN,IN,DT,NN,IN,JJ,NN,NNS,VBZ,JJ,.}","{3,3,14,0,14,0,8,3,0,12,12,8,14,0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_110,"METHOD/LIMITATION : Tissue sections are reviewed by a pathologist and relevant tumor is selected for analysis .","{METHOD/LIMITATION,:,Tissue,sections,are,reviewed,by,a,pathologist,and,relevant,tumor,is,selected,for,analysis,.}","{METHOD/LIMITATION,:,tissue,section,be,review,by,a,pathologist,and,relevant,tumor,be,select,for,analysis,.}","{NNP,:,NN,NNS,VBP,VBN,IN,DT,NN,CC,JJ,NN,VBZ,VBN,IN,NN,.}","{0,0,4,6,6,1,0,9,6,0,12,14,14,6,0,14,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_111,"DNA is isolated from the samples , quantified and amplified by polymerase chain reaction ( PCR ) using primers to eXons 18-21 of the EGFR gene .","{DNA,is,isolated,from,the,samples,,,quantified,and,amplified,by,polymerase,chain,reaction,(,PCR,),using,primers,to,eXons,18-21,of,the,EGFR,gene,.}","{dna,be,isolate,from,the,sample,,,quantify,and,amplify,by,polymerase,chain,reaction,(,pcr,),use,primer,to,eXons,18-21,of,the,egfr,gene,.}","{NN,VBZ,VBN,IN,DT,NNS,,,VBN,CC,VBN,IN,NN,NN,NN,CD,NN,NN,VBG,NNS,TO,NNPS,CD,IN,DT,NN,NN,.}","{3,3,0,0,6,3,0,6,0,6,0,17,17,17,17,17,10,17,18,0,18,8,0,26,26,22,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_112,"PCR products are analyzed by bi ? directional direct DNA sequencing using capillary gel electrophoresis and ?uorescence detection .","{PCR,products,are,analyzed,by,bi,?,directional,direct,DNA,sequencing,using,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{pcr,product,be,analyze,by,bus,?,directional,direct,dna,sequencing,use,capillary,gel,electrophoresis,and,?uorescence,detection,.}","{NN,NNS,VBP,VBN,IN,NN,CD,JJ,JJ,NN,NN,VBG,JJ,NN,NN,CC,NN,NN,.}","{2,4,4,0,0,4,11,11,11,11,4,11,15,15,12,0,18,12,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_113,"False positive or negative results may occur for reasons that include genetic variants or somatic heterogeneity of the tissue sample .","{False,positive,or,negative,results,may,occur,for,reasons,that,include,genetic,variants,or,somatic,heterogeneity,of,the,tissue,sample,.}","{false,positive,or,negative,result,may,occur,for,reason,that,include,genetic,variant,or,somatic,heterogeneity,of,the,tissue,sample,.}","{JJ,JJ,CC,JJ,NNS,MD,VB,IN,NNS,WDT,VBP,JJ,NNS,CC,JJ,NN,IN,DT,NN,NN,.}","{5,5,0,2,7,7,0,0,7,11,9,13,11,0,16,13,0,20,20,16,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_114,"REFERENCES :","{REFERENCES,:}","{reference,:}","{NNS,:}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_115,"DISCLAIMER : This test was develo ed and its perfonnance characteristics detennined bi It has not been cleared or approved by the US Food and Drug Administration .","{DISCLAIMER,:,This,test,was,develo,ed,and,its,perfonnance,characteristics,detennined,bi,It,has,not,been,cleared,or,approved,by,the,US,Food,and,Drug,Administration,.}","{DISCLAIMER,:,this,test,be,develo,ed,and,its,perfonnance,characteristic,detennine,bus,it,have,not,be,clear,or,approve,by,the,US,Food,and,Drug,Administration,.}","{NNP,:,DT,NN,VBD,JJ,NN,CC,PRP$,NN,NNS,VBD,NNS,PRP,VBZ,RB,VBN,VBN,CC,VBN,IN,DT,NNP,NNP,CC,NNP,NNP,.}","{0,0,4,7,7,7,1,0,11,11,12,7,12,20,18,18,18,13,0,18,0,24,24,18,0,27,18,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_116,"The FDA has determined that such clearance or approval is not necessary .","{The,FDA,has,determined,that,such,clearance,or,approval,is,not,necessary,.}","{the,FDA,have,determine,that,such,clearance,or,approval,be,not,necessary,.}","{DT,NNP,VBZ,VBN,IN,JJ,NN,CC,NN,VBZ,RB,JJ,.}","{2,4,4,0,12,7,12,0,12,12,12,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_117,"This test is used for clinical purposes .","{This,test,is,used,for,clinical,purposes,.}","{this,test,be,use,for,clinical,purpose,.}","{DT,NN,VBZ,VBN,IN,JJ,NNS,.}","{2,4,4,0,0,7,4,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_118,"It should not be regarded as investigation or for research .","{It,should,not,be,regarded,as,investigation,or,for,research,.}","{it,should,not,be,regard,as,investigation,or,for,research,.}","{PRP,MD,RB,VB,VBN,IN,NN,CC,IN,NN,.}","{5,5,5,5,5,0,5,0,0,5,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_119,"The laboratory is regulated under the Clinical Laboratory Improvement Amendments o1-CLIA ) as qualified to perfonn high complexity clinical testing .","{The,laboratory,is,regulated,under,the,Clinical,Laboratory,Improvement,Amendments,o1-CLIA,),as,qualified,to,perfonn,high,complexity,clinical,testing,.}","{the,laboratory,be,regulate,under,the,clinical,laboratory,improvement,amendment,o1-clia,),as,qualify,to,perfonn,high,complexity,clinical,testing,.}","{DT,NN,VBZ,VBN,IN,DT,JJ,NN,NN,NNS,JJ,NN,IN,VBN,TO,VB,JJ,NN,JJ,NN,.}","{2,4,4,0,0,10,10,10,10,4,12,4,0,20,16,14,18,16,20,12,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_120,"This particular test is not considered a stand alone test and should be used only in the context of other diagnostic tests or clinical work ? up related to treatment decisions .","{This,particular,test,is,not,considered,a,stand,alone,test,and,should,be,used,only,in,the,context,of,other,diagnostic,tests,or,clinical,work,?,up,related,to,treatment,decisions,.}","{this,particular,test,be,not,consider,a,stand,alone,test,and,should,be,use,only,in,the,context,of,other,diagnostic,test,or,clinical,work,?,up,related,to,treatment,decision,.}","{DT,JJ,NN,VBZ,RB,VBN,DT,NN,RB,NN,CC,MD,VB,VBN,RB,IN,DT,NN,IN,JJ,JJ,NNS,CC,JJ,NN,RB,RB,JJ,TO,NN,NNS,.}","{3,3,14,6,6,0,10,10,10,6,0,14,14,6,14,0,18,14,0,22,22,18,0,25,27,25,28,6,0,31,28,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_121,"Date :","{Date,:}","{date,:}","{NN,:}","{0,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_122,"Addendum # 3 erformed by","{Addendum,#,3,erformed,by}","{Addendum,#,3,erform,by}","{NNP,#,CD,VBN,IN}","{0,3,1,1,4}","{}"
TCGA-97-8172, TCGA-97-8172SENT_123,"Electronically signed The electronic signature attests that the named Attending Pathologist has evaluated the specimen referred to in the signed section of the report and fonnulated the diagnosis therein .","{Electronically,signed,The,electronic,signature,attests,that,the,named,Attending,Pathologist,has,evaluated,the,specimen,referred,to,in,the,signed,section,of,the,report,and,fonnulated,the,diagnosis,therein,.}","{electronically,sign,the,electronic,signature,attest,that,the,name,attend,pathologist,have,evaluate,the,specimen,refer,to,in,the,sign,section,of,the,report,and,fonnulate,the,diagnosis,therein,.}","{RB,VBN,DT,JJ,NN,VBZ,IN,DT,VBN,VBG,NN,VBZ,VBN,DT,NN,VBD,TO,IN,DT,VBN,NN,IN,DT,NN,CC,VBD,DT,NN,RB,.}","{2,6,5,5,2,0,13,13,8,9,10,13,6,15,26,13,16,0,21,21,16,0,24,21,0,16,28,26,26,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_124,"This report may include one or more immunohistochemical stain results that use analyte specific reagents .","{This,report,may,include,one,or,more,immunohistochemical,stain,results,that,use,analyte,specific,reagents,.}","{this,report,may,include,one,or,more,immunohistochemical,stain,result,that,use,analyte,specific,reagent,.}","{DT,NN,MD,VB,CD,CC,JJR,JJ,VB,NNS,WDT,VBP,NN,JJ,NNS,.}","{2,4,4,0,8,0,8,9,4,9,12,10,15,15,12,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_125,"The tests were develo ed and their erformance characteristics","{The,tests,were,develo,ed,and,their,erformance,characteristics}","{the,test,be,develo,ed,and,they,erformance,characteristic}","{DT,NNS,VBD,JJ,NN,CC,PRP$,NN,NNS}","{2,5,5,5,0,0,9,9,5}","{}"
TCGA-97-8172, TCGA-97-8172SENT_126,"They have not been cleared or approved by the US Food and Drug Administration .","{They,have,not,been,cleared,or,approved,by,the,US,Food,and,Drug,Administration,.}","{they,have,not,be,clear,or,approve,by,the,US,Food,and,Drug,Administration,.}","{PRP,VBP,RB,VBN,VBN,CC,VBN,IN,DT,NNP,NNP,CC,NNP,NNP,.}","{7,5,5,5,0,0,5,0,11,11,5,0,14,5,0}","{}"
TCGA-97-8172, TCGA-97-8172SENT_127,"The FDA has detennined that such clearance or approval is not necessary .","{The,FDA,has,detennined,that,such,clearance,or,approval,is,not,necessary,.}","{the,FDA,have,detennine,that,such,clearance,or,approval,be,not,necessary,.}","{DT,NNP,VBZ,VBN,IN,JJ,NN,CC,NN,VBZ,RB,JJ,.}","{2,4,4,0,12,7,12,0,12,12,12,4,0}","{}"
